

PHARMACEUTICAL 2023

AGILE THERAPEUTICS INC Rank 393 of 446









PHARMACEUTICAL 2023

AGILE THERAPEUTICS INC Rank 393 of 446



The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 128% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -205%, being 249% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,358
Cost of Goods Sold	6,836
Intangible Assets	0
Liabilities, Current	13,387
Liabilities, Non-Current	466
Other Assets	2,707
Other Compr. Net Income	0
Other Expenses	36,816
Other Liabilities	5,934
Other Net Income	22,469
Other Revenues	10,884
Property and Equipment	177
Research and Development	3,253
Selling, General and Administrative Expense	11,860

Output Variable	Value in 1000 USD
Assets	14,242
Liabilities	19,787
Expenses	58,765
Revenues	10,884
Stockholders Equity	-5,545
Net Income	-25,412
Comprehensive Net Income	-25,412
Economic Capital Ratio	-205%

